Cronus Pharma Launches First FDA-Approved Bioequivalent Robenacoxib Injection for Veterinary Use

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Cronus Pharma Launches First FDA-Approved Bioequivalent Robenacoxib Injection for Veterinary UseAuthor of the article:Business Wire Business WireFirst bioequivalent to ONSIOR® (robenacoxib) Injection equips veterinarians with new, cost-effective NSAID (nonsteroidal anti-inflammatory) option for controlling postoperative pain and inflammation with certain surgical procedures in dogs and cats.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountEAST BRUNSWICK, N.J. — Cronus Pharma LLC, a veterinary pharmaceutical company focused on developing high-quality, cost-effective animal health products, today announced the U.S. launch of Robenacoxib Injection, the only FDA-approved bioequivalent to ONSIOR® (robenacoxib) Injection.First bioequivalent to ONSIOR® (robenacoxib) Injection equips veterinarians with new, cost-effective NSAID (nonsteroidal anti-inflammatory) option for controlling postoperative pain and inflammation with certain surgical procedures in dogs and cats.Robenacoxib Injection is indicated for the control of postoperative pain and inflammation associated with soft tissue surgery in dogs ≥ 4 months of age, and with orthopedic surgery, ovariohysterectomy and castration in cats ≥ 4 months of age; in each case for up to a maximum of 3 days. The product is now available for purchase through national and regional veterinary distributors across the United States.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try again“Addressing post-operative pain is imperative in both dogs and cats,” said Scott A. Krick DVM – Consulting Technical Services Veterinarian at Cronus Pharma. “The launch of Robenacoxib Injection from Cronus Pharma provides a cost-effective NSAID option and reflects our commitment to expanding access to FDA-approved bioequivalent medications that support veterinarians, their patients, and pet owners.”“The launch of Robenacoxib Injection marks an important addition to Cronus Pharma’s growing portfolio of FDA-approved veterinary products,” said Janel Fisher, Vice President of Sales at Cronus Pharma. “Innovation is at the heart of what we do, and we are continually looking for opportunities to bring meaningful new products to the veterinary market. This launch demonstrates our ability to turn that commitment to innovation into solutions that provide greater choice and value for the veterinary community.”About Robenacoxib Injection:Indicated for the control of postoperative pain and inflammation associated with soft tissue surgery in dogs ≥ 4 months of age, and with orthopedic surgery, ovariohysterectomy and castration in cats ≥ 4 months of age; in each case for up to a maximum of 3 days.Available as a 20 mg/mL solution in a 20 mL multidose vial.FDA approved as bioequivalent to the reference listed new animal drug, ONSIOR® (robenacoxib) InjectionApproved by FDA under ANADA # 200-804.Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use for more than three days, or in animals less than four months of age. Serious adverse events have been reported, including hepatopathy, with the long-term use (28-day study) of Robenacoxib tablets in dogs.Based in East Brunswick, New Jersey, Cronus Pharma is a privately held veterinary generic pharmaceutical company dedicated to advancing animal health. With integrated research, development, manufacturing, and marketing, we deliver innovative and cost-effective solutions for animals. Our passionate team of scientists is actively developing new products, with a robust pipeline awaiting FDA approval. Cronus Pharma is committed to supporting veterinarians and pet owners with high-quality, accessible solutions.Learn more about our mission to enhance animal health at www.cronuspharmausa.com.ONSIOR Injection is a registered trademark of Elanco US Inc.View source version on businesswire.com: Phone: 844-2-CRONUS (844-227-6687)This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.